| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Collaboration revenue | 2,054 | 2,412 | 1,451 | |
| Research and development | 18,513 | 19,844 | 11,109 | |
| General and administrative | 6,681 | 7,339 | 6,788 | |
| Total operating expenses | 25,194 | 27,183 | 17,897 | |
| Loss from operations | -23,140 | -24,771 | -16,446 | |
| Interest expense | 149 | 201 | 255 | |
| Interest and other income (expense), net | 3,160 | 3,420 | 3,714 | |
| Gain (loss) from changes in fair value of warrants | -42 | -11 | 59 | |
| Loss on extinguishment of debt | 0 | 0 | - | |
| Total other income (expense), net | 2,969 | 3,208 | 3,518 | |
| Net loss | -20,171 | -21,563 | -12,928 | |
| Unrealized holding gains on available-for-sale investments | 73 | 0 | 29 | |
| Foreign currency translation adjustment | -10 | -52 | -10 | |
| Total other comprehensive income | 63 | -52 | 19 | |
| Total comprehensive loss | -20,108 | -21,615 | -12,909 | |
| Earnings per share, basic, total | -0.56 | -0.6 | -0.36 | |
| Net loss per share attributable to common stockholders, diluted | -0.56 | -0.6 | -0.36 | |
| Weighted average number of shares outstanding, basic, total | 35,850,037 | 35,850,037 | 35,850,037 | |
| Weighted average number of shares outstanding, diluted, total | 35,850,037 | 35,850,037 | 35,850,037 | |
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)